Takeda gets FDA breakthrough therapy status for pevonedistat to treat higher-risk HR-MDS

This article was originally published here

MDS is a rare form of bone marrow-related cancer, which will be resulted due to irregular blood cell production within the bone marrow. Pevonedistat, a first-in-class NEDD8-activating enzyme

The post Takeda gets FDA breakthrough therapy status for pevonedistat to treat higher-risk HR-MDS appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply